HER-2-таргетная терапия рака молочной железы: моноклональные антитела и ингибиторы тирозинкиназы


Цитировать

Полный текст

Аннотация

Лапатиниб (Тайверб) – новый двойной ингибитор тирозинкиназы, действующий на молекулы EGFR (HER-1) и ErbB2 (HER-2), на Akt, а также инактивирующий MAPK. Преклинические исследования продемонстрировали подавление роста и индукцию апоптоза в клеточных линиях рака молочной железы (РМЖ). In vitro синергетический эффект наблюдался с трастузумабом. В дальнейшем было установлено, что лапатиниб способен восстанавливать чувствительность к тамоксифену. Результаты I–II фазы исследований позволили предположить, что данное вещество обладает активностью в отношении ряда опухолей, особенно РМЖ

Об авторах

И Н Огнерубова

ГОУ ДПО РМАПО, Москва

Кафедра онкологии

Список литературы

  1. Nahta R, Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett 2006; 232 (5): 123–38.
  2. Burstein H.J., Harris L.N., Marcom P.K. et al. Trastuzumab and vinorelbine as first - line therapy for HER-2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algoritm. J Clin Oncol 2003; 21 (15): 2889–95.
  3. Konecny G, Pauletti G, Pergram M. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor - positive breast cancer. J Natl Cancer Inst 2003; 95 (2): 142–53.
  4. Jones A. Combining trastuzumab (Herceptin®) with hormonal therapy in breast cancer: what can be expected and why? Ann Oncol 2003; 14 (12): 1697–704.
  5. Johnston S.R.D., Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003; 3 (11): 821–31.
  6. Jackisch C. HER-2 positive metastatic breast cancer: optimizing trastuzumab - based therapy. Oncologust 2006; 11 (Suppl.): 34–41.
  7. Shou J, Massarwen S, Osborne C.K. et al. Mechanisms of tamoxifen resistance. increased estrogen receptor-HER-2/neu cross - talk in ER/HER-2 - positive breast cancer. J Natl Cancer Inst 2004; 96 (12): 926–35.
  8. Ocana A, Cruz J, Pandiella A. Trastuzumab and antiestrogen therapy. Focus on mechanisms of action and resistance. Am J Clin Oncol 2006; 29 (1): 90–5.
  9. Toi M, Horiguchi K, Bando H et al. Trastuzumab: updates and future issues. Cancer Chemother Pharmacol 2005; 56 (Suppl. 1): s94–9.
  10. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal - receptor - positive breast cancer with co - expression of HER-2. Nat Clin Prac Oncol 2008; 5 (9): 531–42.
  11. Konecny G.E., Pergram M.D., Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab treated breast cancer cells. Cancer Res 2006; 66 (3): 1630–9.
  12. Xia W, Mullin R.J., Keith B.R. et al. Antitumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erb2 and downstream Erk1/2 and EKT pathway. Oncogene 2002; 21 (41): 6255–63.
  13. Nelson M.H., Dolder D.R. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006; 40 (2): 261–9.
  14. Rusnak D.W., Lackey K, Affleck K et al. The effect of the novel, reversible epidermal growth of human normal and tumor - derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1 (2): 85–94.
  15. Gomez H.L., Chavez M.A., Doval D.C. et al. Results from a phase II randomized study of lapatinib as first - line treatment for patient with HER-2 - amplified locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl. 1): abstract 1090.
  16. Burstein H.J., Storniolo A.M., Franco S et al. A phase II study of lapatinib monotherapy in chemotherapy - refractory HER-2 - positive and HER-2 - negative advanced or metastatic breast cancer. Ann Oncol 2008; 19 (6): 1068–74.
  17. Iwata H, Toi M, Fujiwara Y et al. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl. 1): abstr. 1091.
  18. Johnston S.R.D., Trudeau M, Kaufman B et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008; 26 (7): 1066–72.
  19. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysis. Breast Cancer Res Treat 2008 Jan 11. Epub ahead of print.
  20. Di Leo A, Gomez H, Aziz Z et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first - line treatment for patients with metastatic breast cancer: a phase III randomized, double - blind study of 580 patients. J Clin Oncol 2007; 25 (18S): abstr. 1011.
  21. Cameron D.A., Stein S. Drug insight: intracellular inhibitors of HER-2 - clinical development of lapatinib in breast cancer. Nat Clin Prac Oncol 2008; 5 (9): 512–9.
  22. Clayton A.J., Danson S, Lolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91 (4): 639–43.
  23. Montagna E, Cancello G, D’Agostino D et al. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. Cancer Chemother Pharmacol 2008 Apr 1. Epub ahead of print.
  24. Torresi U. Trastuzumab - treated advanced breast cancer patients and brain metastases: just a little alert. Ann Oncol 2008; 19 (1): 191.
  25. Stemmler H.J., Schmitt M, Willems A et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER-2 - positive breast cancer patients with brain metastases and impairment of blood - brain barrier. клиническая онкология Anticancer Drugs 2007; 18 (1): 23–82.
  26. Burris H.A. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/erbB-2 inhibitor lapatinib. Oncologist 2004; 9 (Suppl. 3): 10–5.
  27. Lin N.U., Carey L.A., Liu M.C. et al. Phese II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2 - positive breast cancer. J Clin Oncol 2008; 26 (12): 1993–9.
  28. Cianfrocca M.E., Rosen S.T., von Roenn J.H. et al. A phase I trial of pegylated liposomal anthracycline and lapatinib (L) combination in the treatment of metastatic breast cancer (MBC): first evaluation of an anthracycline and lapatinib combination in the treatment MBC. J Clin Oncol 2007; 25 (S18): abstr. 1079.
  29. Hobday T.J., Perez E.A. Molecularly targeted therapies for breast cancer. Cancer Control 2005; 12 (2): 73–81.
  30. Xia W, Bacus S, Hegde P et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006; 103 (20): 7795–800.
  31. Wenham N, D’Hondt V, Piccart M.J. HER-2 - positive breast cancer: from trastuzumab to innovatory anti - HER-2 strategies. Clin Breast Cancer 2008; 8 (1): 38–49.
  32. Moy B, Goss P.E. TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer 2007; 7 (6): 489–92.
  33. Guarneri V, Frassoldati A, Piacentini F et al. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER-2 - positive operable breast cancer (CHERLOB trial). Clin Breast Cancer 2008; 8 (2): 192–4.
  34. Frassoldati A, Guarneri V, Piacentini F et al. Letrozole versus letrozole plus lapatinib (GW572016) in hormone - sensitive, HER-2 - negative operable breast cancer; a doubl - blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). Clin Breast Cancer 2008; 8 (1): 97–100.
  35. Moy B, Goss P.E. Lapatinib: current status and future directions in breast cancer. Oncologist 2006; 11 (10): 1047–57.
  36. Bacus S.S., Trusk P, Lyass L et al. Inhibition of ErbB1/2 by small molecule tyrosine kinase inhibitors, but not trastuzumab, affects metabolic pathways: implications to cardiac toxicity. Breast Cancer Res Treat 2006; 100 (Suppl. 1): abstr. 304.
  37. Perez E.A., Byrne J.A., Hammond I.W. et al. Results of analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol 2006; 24 (S18): abstr. 583.
  38. Allen L.F., Eiseman I.A., Fry D.W., Lenehan P.F. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol 2003; 30 (5 Suppl. 16): 65–78.
  39. Nemunaitis J, Eiseman I.A., Cunningham C et al. Phase I clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 2005; 11 (10): 3846–53.
  40. Garland L.L., Hidalgo M, Mendelson D et al. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2006; 12 (14Pt 1): 4274–82.
  41. Rabindran S.K., Disfani C.M., Rosfjord E.C. et al. Antitumor activity of HKI - 272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004; 64 (11): 3958–65.
  42. Wohg K.K., Fracasso P.M., Bukowski R.M. et al. HKI-272, an irreversible panerbB receptor tyrosine kinase inhibitor; preliminary phase 1 results in patients with solid tumors. J Clin Oncol 2006; 24 (S18): abstr. 3018.
  43. Burstein H.J., Awada A, Badwe R et al. HKI-272, an irreversible panerbB receptor tyrosine kinase inhibitor; preliminary phase 2 results in patients with advanced breast cancer. Breast Cancer Res Treat 2007; 106 (Suppl. 1): abstr. 6061.
  44. Emanuel S.L., Hughes T.V., Adams M et al. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan - ErbB kinase inhibitor that crosses the blood - brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 2008; 73 (2): 338–48.
  45. Lan K.H., Lu C.H., Yu D. Mechanisms of trastuzumab resistance and their clinical implications. Ann N Y Acad Sci 2005; 1059: 70–5.
  46. Piccart M. Circumventing de novo and required resistance to trastuzumab: new hope for the care of ErbB - positive breast cancer. Clin Breast Cancer 2008; 8 (Suppl. 3): S100–13.
  47. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER-2 - overexpressing breast cancer. Ann Oncol 2007; 18 (6): 977–84.
  48. Friedlander E, Barok M, Szolossi J, Vereb G. ErbB - directed immunotherapy: antibodies in current practice and promising new agents. Immunology Letters 2008; 116 (2): 126–40.
  49. Price-Schiavi S.A., Jepson S, Li P. Rat Muc4 (sialomucin complex) reduces binding of anti - ErbB antibodies to tumor cell surfaces, a potential mechanism for Herceptin resistance. Int J Cancer 2002; 99 (6): 783–91.
  50. Nagy P, Friedlender E, Tanner M et al. Decreased accessibility and lack of activation of ErbB in JIMT-1, a herceptin - resistant, MUC-4 expressing breast cancer cell line. Cancer Res 2005; 65 (2): 473–82.
  51. Molina M.A., Saez R, Ramsey E.E. et al. NH(2) - terminal truncated HER-2 protein but not full - length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002; 8 (2): 347–53.
  52. Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER-2, a truncated form of the HER-2 receptor, and response to anti - HER-2 therapies in breast cancer. J Natl Cancer Inst 2007; 99 (8): 628–38.
  53. Borras A.M., Rogers A, Kuang Y et al. Identification of novel splice variants in breast cancer. J Clin Oncol 2008; 26 (Suppl.): abstr. 22010.
  54. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors expressing HER-2. Clin Cancer Res 2004; 10 (17): 5650–5.
  55. Diermeier S, Norvath G, Knuechel-Clarke R et al. Epidermal growth factor receptor coexpression modulates sysceptibility to Herceptin in HER-2/neu overexpressing breast. Exp Cell Res 2005; 304 (2): 604–19.
  56. Brockhoff G, Heckel B, Schmidt-Bruecken E et al. Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007; 40 (4): 488–507.
  57. Bender L.M., Nahta R. HER-2 cross talk and therapeutic resistance in breast cancer. Front Biosci 2008; 13 (May 1): 3906–12.
  58. Motoyama A.B., Hynes N.E., Lane H.A. The efficacy of ErbB receptor - targeted anticancer therapeutics is influenced by the availability of epidermal growth factor - related peptides. Cancer Res 2002; 62 (11): 3151–8.
  59. Valabrega G, Montemurro F, Sarotto I et al. TGFalpha expression impairs trastuzumab - induced HER-2 downregulation. Oncogene 2005; 24 (18): 3002–10.
  60. Robinson A.G., Turbin D, Thomson T et al. Molecular predictive factors in patients receiving trastuzumab - based chemotherapy for metastatic disease. Clin Breast Cancer 2006; 7 (3): 254–61.
  61. Wang S.E., Xiang B, Guix M et al. Transforming growth factor α engages TACE and ErbB3 to activate PI3K/Akt in erbB2 - overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 2008 doi: 10.1128/MCB.00787-08.14. July 2008. Epub ahead of print.
  62. Press M.F., Finn R.S., Di Leo A et al. Correlation of HER-2 gene amplification, HER-2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer. J Clin Oncol 2008; 26 (Suppl.): abstr. 1007.
  63. Casa A.J., Dearth R.K., Litzenburger B.C. et al. The type I insulin - like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 2008; 13: 3273–87.
  64. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I - induced attenuation of the growth – inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004; 108 (3): 334–41.
  65. Nahta R, Yuan L.X., Zhang B et al. Insulin - like growth factor - I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65 (23): 11118–28.
  66. Spector N.L., Xia W, Burris 3rd H et al. Study of biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23 (11): 2502–12.
  67. Yakes F.M., Chinratanalab W, Ritter C.A. et al. Herceptin - induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibodymediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62 (14): 4132–41.
  68. Nagata Y, Lan K.H., Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6 (2): 117027.
  69. Berns K, Horlings H.M., Henessy B.T. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12 (4): 395–402.
  70. Pegram M, Perez E.A., Piccart M, Spector N. Expert roundtable: emerging questions in ErbB2 - positive breast cancer; February 22, 2007. Clin Brest Cancer 2008; 8 (Suppl. 3): S131–41.
  71. Nahta R, Takanashi T, Ueno N.T. et al. P27 (kip1) downregulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004; 64 (11): 3981–6.
  72. Singer C.F., Kostler W.J., Hudelist G. Predicting the efficacy of trastuzumab - based therapy in breast cancer: current standard and future strategies. Biochim Biophys Acta 2008 Mar 4. Epub ahead of print.

© ООО "Консилиум Медикум", 2009

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах